posted on 2023-02-06, 10:11authored byEleanor Woodward, Minjun YangMinjun Yang, Larissa Helena Moura-Castro, Hilda van den Bos, Rebeqa GunnarssonRebeqa Gunnarsson, Linda Olsson Arvidsson, Diana C. J. Spierings, Anders Castor, Nicolas Duployez, Marketa Zaliova, Jan Zuna, Bertil Johansson, Floris Foijer, Kajsa Paulsson
<p> </p>
<p>This dataset included 577 samples with high hyperdiploid acute lymphoblastic leukemia (ALL) that were collected from four different cohorts: the Division of Clinical Genetics, Lund University, Sweden, Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University/University Hospital Motol, Prague, Czech Republic (Zaliova et al., 2016), Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France (Duployez et al., 2018), and The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) program (NCBI dbGAP accession number phs00464). All samples were genotyped using either the Affymetrix SNP Array, Illumina's BeadArray platform or the whole genome/exome sequencing. Copy number alterations analysis was performed using Tumor Aberration Prediction Suite (TAPS, Rasmussen et al., 2011) and the graphics produced by TAPS are available for download. The interpretation of the figure is available at: https://patchwork.r-forge.r-project.org. This dataset has been used for copy number aberrations analysis for high hyperdiploid ALL.</p>
Funding
The role of CTCF and cohesin in leukemia development